EpiVax Inc - Company Profile
Powered by 
All the data and insights you need on EpiVax Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date EpiVax Inc Strategy Report
- Understand EpiVax Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
EpiVax Inc (EpiVax) develops analytical capabilities in the field of computational immunology. Its product pipeline includes Tregitopes; deimmunization projects including deimmunized botox and deimmunized FVIII; and biodefense vaccines. Tregitopes are linear sequences of amino acids which activate natural regulatory T cells. It is an immune-modulation power tool that is being developed for auto-immune, auto-inflammatory and allergic conditions. EpiVax’ service portfolio includes immune engineering, immunogenicity screening, vaccine design, and redesign. The company also provides lab services such as in vivo, in vitro and ex vivo immunogenicity screening services including cell-free HLA binding assays. EpiVax is headquartered in Providence, Rhode Island, the US.
Headquarters
United States of America
Address
Suite 424, 188 Valley Street, Providence, Rhode Island, 02909
Website
www.epivax.com
Telephone
1 401 2722123
Industry
Pharmaceuticals and Healthcare
EpiVax Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Product Pipeline: | Vaccine Design and Redesign |
| Tregitope- Immuno-Modulation Power Tool | Immunogenicity Screening |
| Deimmunized Botox- Deimmunization | Immune Engineering |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In January, the company and Zoetis announced their agreement to collaborate on Swine T cell Epitope Prediction Tool: CircoMatch. |
| 2023 | Contracts/Agreements | In January, the company and Greenlight announced their agreement to develop personalized cancer vaccines. |
| 2022 | Contracts/Agreements | In October, the company announced its participation in a new project with intravacc, which is being funded by the coalition for epidemic preparedness innovations. |
Competitor Comparison
| Key Parameters | EpiVax Inc | Jounce Therapeutics Inc | VBI Vaccines Inc | Advanced BioScience Laboratories Inc | BioFactura Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Providence | Cambridge | Cambridge | Rockville | Frederick |
| State/Province | Rhode Island | Massachusetts | Massachusetts | Maryland | Maryland |
| No. of Employees | - | 141 | 190 | - | - |
| Entity Type | Private | Private | Public | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Anne S. De Groot, Ph.D., M.D. | Chief Executive Officer; Chief Scientific Officer | Senior Management | - | - |
| Clifford Grimm | Managing Director; Chief Business Officer; Chief Financial Officer | Senior Management | - | - |
| William Martin | Chief Operating Officer; Chief Information Officer | Senior Management | - | - |
| Matthew Ardito | Director - IT | Senior Management | 2021 | - |
| Aimee Mattei | Director - Bioinformatics | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer